Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL⁺ human leukemia"

Damian Lai^{1

2}, Min Chen¹, Jiechuang Su^{1

3}, Xiaohu Liu^{1

2}, Katharina Rothe^{1

3}, Kaiji Hu¹, Donna L Forrest^{2

4}, Connie J Eaves^{1

2

3}, Gregg B Morin^{3

5}, Xiaoyan Jiang^{6

2

3}

Affiliations

¹ Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
² Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
³ Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
⁴ Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC V5Z 1M9, Canada.
⁵ Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
⁶ Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada. xjiang@bccrc.ca.

PMID: 31316004
DOI: 10.1126/scitranslmed.aav0819

Comment

Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL⁺ human leukemia"

Damian Lai et al. Sci Transl Med. 2019.

. 2019 Jul 17;11(501):eaav0819.

doi: 10.1126/scitranslmed.aav0819.

Authors

Affiliations

¹ Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
² Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
³ Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
⁴ Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC V5Z 1M9, Canada.
⁵ Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
⁶ Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada. xjiang@bccrc.ca.

PMID: 31316004
DOI: 10.1126/scitranslmed.aav0819

Abstract

LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.

PubMed Disclaimer

Comment on

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL⁺ human leukemia.
Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, Forrest DL, Eaves CJ, Morin GB, Jiang X. Lai D, et al. Sci Transl Med. 2018 Feb 7;10(427):eaan8735. doi: 10.1126/scitranslmed.aan8735. Sci Transl Med. 2018. PMID: 29437150
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM. Perrotti D, et al. Sci Transl Med. 2019 Jul 17;11(501):eaau0416. doi: 10.1126/scitranslmed.aau0416. Sci Transl Med. 2019. PMID: 31316003 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL⁺ human leukemia"

Affiliations

Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL⁺ human leukemia"

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous